Literature DB >> 8411033

Facioscapulohumeral muscular dystrophy: aspects of genetic counselling, acceptance of preclinical diagnosis, and fitness.

S Eggers1, M R Passos-Bueno, M Zatz.   

Abstract

A questionnaire about the interest in and demand for preclinical diagnosis for facioscapulohumeral muscular dystrophy (FSH) was sent to 46 patients. Most stated that they would have liked to have known their diagnosis earlier in order to seek more efficient help, to avoid strenuous activities, to prepare themselves emotionally, or to choose an appropriate profession. Similar arguments were used to explain their interest in preclinical diagnosis for their children. Most patients also favoured prenatal diagnosis although only two stated they would abort a pregnancy in the case of an affected fetus. Genetic counselling had apparently little influence on family planning. According to this study, FSH does not seem to reduce reproductive performance in our population.

Entities:  

Mesh:

Year:  1993        PMID: 8411033      PMCID: PMC1016460          DOI: 10.1136/jmg.30.7.589

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  21 in total

1.  Deletion of a DNA sequence at the chromosomal region 3p21 in all major types of lung cancer.

Authors:  K Kok; J Osinga; B Carritt; M B Davis; A H van der Hout; A Y van der Veen; R M Landsvater; L F de Leij; H H Berendsen; P E Postmus
Journal:  Nature       Date:  1987 Dec 10-16       Impact factor: 49.962

2.  Sotos syndrome with a balanced reciprocal translocation t(2;12)(q33.3;q15).

Authors:  K Tamaki; K Horie; T Go; T Okuno; H Mikawa; Z Y Hua; T Abe
Journal:  Ann Genet       Date:  1989

3.  Neuroblastoma in a patient with Sotos' syndrome.

Authors:  M A Nance; J P Neglia; D Talwar; S A Berry
Journal:  J Med Genet       Date:  1990-02       Impact factor: 6.318

4.  Sotos syndrome and de novo balanced autosomal translocation (t(3;6)(p21;p21))

Authors:  C T Schrander-Stumpel; J P Fryns; G G Hamers
Journal:  Clin Genet       Date:  1990-03       Impact factor: 4.438

5.  Cerebral gigantism associated with Wilms' tumor.

Authors:  V Maldonado; P S Gaynon; A K Poznanski
Journal:  Am J Dis Child       Date:  1984-05

6.  Loss of allelic heterozygosity at a second locus on chromosome 11 in sporadic Wilms' tumor cells.

Authors:  A E Reeve; S A Sih; A M Raizis; A P Feinberg
Journal:  Mol Cell Biol       Date:  1989-04       Impact factor: 4.272

7.  Cerebral gigantism (Sotos syndrome). Compiled data of 22 cases. Analysis of clinical features, growth and plasma somatomedin.

Authors:  J M Wit; F A Beemer; P G Barth; J W Oorthuys; P F Dijkstra; J L Van den Brande; N J Leschot
Journal:  Eur J Pediatr       Date:  1985-07       Impact factor: 3.183

8.  A nonrandom chromosomal abnormality, del 3p(14-23), in human small cell lung cancer (SCLC).

Authors:  J Whang-Peng; P A Bunn; C S Kao-Shan; E C Lee; D N Carney; A Gazdar; J D Minna
Journal:  Cancer Genet Cytogenet       Date:  1982-06

9.  The Perlman syndrome: familial renal dysplasia with Wilms tumor, fetal gigantism and multiple congenital anomalies.

Authors:  G Neri; M E Martini-Neri; B E Katz; J M Opitz
Journal:  Am J Med Genet       Date:  1984-09

10.  Loss of heterozygosity in three embryonal tumours suggests a common pathogenetic mechanism.

Authors:  A Koufos; M F Hansen; N G Copeland; N A Jenkins; B C Lampkin; W K Cavenee
Journal:  Nature       Date:  1985 Jul 25-31       Impact factor: 49.962

View more
  2 in total

1.  High proportion of new mutations and possible anticipation in Brazilian facioscapulohumeral muscular dystrophy families.

Authors:  M Zatz; S K Marie; M R Passos-Bueno; M Vainzof; S Campiotto; A Cerqueira; C Wijmenga; G Padberg; R Frants
Journal:  Am J Hum Genet       Date:  1995-01       Impact factor: 11.025

2.  How the magnitude of clinical severity and recurrence risk affects reproductive decisions in adult males with different forms of progressive muscular dystrophy.

Authors:  S Eggers; M Zatz
Journal:  J Med Genet       Date:  1998-03       Impact factor: 6.318

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.